Compare Adaptive Biotechnologies Corp (ADPT) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Rockwell Automation — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while Rockwell Automation trades at $461.81 (market cap $52.18B). The key difference: Rockwell Automation is far larger — about 15.7× Adaptive Biotechnologies Corp's market cap, and Rockwell Automation pays a 1.18% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ROK | |
|---|---|---|
Market Cap | $3.33B | $52.18B |
Sector | Health | Industrials |
52-Week High | $22.37 | $495.08 |
52-Week Low | $10.24 | $328.67 |
Enterprise Value | $3.19B | $55.81B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Rockwell Automation (ROK) trades at $468.9, down 0.59% today but near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Revenue remains stable at $8.34B (2025), though net margins have softened to 10.41%. Recent news highlights AI infrastructure opportunities and product launches like FactoryTalk Orchestration, positioning ROK for industrial digital transformation growth.
Outlook remains positive with analyst consensus leaning toward Hold/Buy, targeting $463.86. Key opportunities include AI-driven industrial automation demand, while risks involve margin pressure and cyclical industry exposure. Valuation multiples (P/E 50.14) suggest premium pricing, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
